Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination therapy** of a *polyherbal formulation* (typically derived from Traditional Chinese Medicine formulas such as Yin-Qiao-San and Sang-Ju-Yin, or their components) and **oseltamivir**, an antiviral medication. Oseltamivir is a neuraminidase inhibitor used to treat and prevent influenza A and B by inhibiting the viral neuraminidase, thereby blocking the release of new viral particles. The polyherbal formulation may contain multiple plant-derived components with purported antiviral, immunomodulatory, and anti-inflammatory actions. Studies (such as those examining the combined use of oseltamivir with herbal formulas like CMF1 or with individual herbs like Radix Scutellariae) suggest that polyherbal formulations can alter the pharmacokinetics of oseltamivir, such as increasing the absorbed fraction of oseltamivir and inhibiting its hydrolysis, but do not significantly alter its antiviral activity in vivo[1]. The role of such combinations is primarily being investigated for improved influenza management, especially in traditional medicine contexts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyherbal formulation + oseltamivir.